AH-7921

AH-7921 structure

AH-7921 3D BS.png

AH-7921 is a synthetic opioid analgesic that was first synthesized in the 1970s by a team of scientists at Allen and Hanburys, a pharmaceutical company. It is known for its potent analgesic effects and has been compared to morphine in terms of its efficacy.

Chemical Structure and Properties

AH-7921 is chemically classified as a benzamide. Its IUPAC name is 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide. The compound has a molecular formula of C16H22Cl2N2O and a molecular weight of 329.26 g/mol.

Pharmacology

AH-7921 acts as a potent mu-opioid receptor agonist. It binds to the mu-opioid receptors in the brain and spinal cord, which are responsible for the analgesic and euphoric effects of opioids. The drug has been shown to produce effects similar to those of other opioids, such as morphine and heroin, including pain relief, euphoria, and sedation.

Medical Use

Despite its potent analgesic properties, AH-7921 has never been approved for medical use. Its potential for abuse and addiction, along with its adverse effects, has limited its development as a therapeutic agent.

Adverse Effects

The adverse effects of AH-7921 are similar to those of other opioids and can include:

• Respiratory depression
• Nausea and vomiting
• Constipation
• Drowsiness
• Dependence and addiction

Legal Status

AH-7921 has been classified as a controlled substance in many countries due to its potential for abuse and lack of medical use. In the United Kingdom, it was classified as a Class A drug under the Misuse of Drugs Act in 2015. In the United States, it is listed as a Schedule I controlled substance under the Controlled Substances Act.

Synthesis

The synthesis of AH-7921 involves the reaction of 3,4-dichlorobenzoyl chloride with 1-dimethylamino-2-cyclohexylmethylamine. The process requires careful control of reaction conditions to ensure the purity and yield of the final product.

See Also

• Opioid
• Mu-opioid receptor
• Morphine
• Heroin
• Controlled Substances Act